The U.S. Food and Drug Administration’s reviewers have raised efficacy concerns over Otsuka Pharma’s combination drug for adults with PTSD, citing inconsistent trial results and a modest treatment effect that may not be clinically meaningful. The FDA staff reviewers’…
